FDA Clears Qiagen's HSV-1/2 MDx Kit | GenomeWeb

NEW YORK(GenomeWeb) – Qiagen said after the close of the market on Thursday that the US Food and Drug Administration cleared the artus HSV-1/2 QS-RGQ kit for molecular diagnosis of herpes simplex virus type 1 and type 2 infections.

FDA cleared the HSV-1/2 kit in late December to run on the QIAsymphony RGQ molecular diagnostics system. Qiagen said the assay was its fifth in 2014 to receive FDA clearance or approval.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.